SK Chemical to agree exclusive distribution of TMX-67.

Published: 2004-08-06 06:56:00

Updated: 2004-08-06 06:56:00

SK Chemical and SK pharmaceutical division made a technical licence agreement with Japanese Deijin on July 13 for an exclusive distribution of TMX-67 (febuxostat) in Korea, a new compound for the treatment of gout, the health registration of which is still underway in Japan.

TMX-67 is an oral...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK